BCL2L1 and colorectal carcinoma: Oxaliplatin and bortezomib induce the dissociation of Bcl-xL from Beclin 1 and initiate autophagy in CRC cells [46]. Prevents CRC cell apoptosis, drives tumorigenesis and cancer progression [41].